Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 28Leukemia, Myeloid, Acute 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 23Lymphoma 22Small Cell Lung Carcinoma 20Burkitt Lymphoma 19Lymphoma, Non-Hodgkin 18Lung Neoplasms 13Recurrence 12Neuroblastoma 12Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Congenital Abnormalities 12Myelodysplastic Syndromes 11Lymphoma, Follicular 11Brain Neoplasms 10Hodgkin Disease 9Carcinoma, Non-Small-Cell Lung 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Accelerated Phase 8Leukemia, Monocytic, Acute 8Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Blast Crisis 8Sarcoma 7Neoplasms 7Myeloproliferative Disorders 7Multiple Myeloma 7

Interventions

atezolizumab 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × SCLC,Extensive Stage × Etoposide × Clear all
NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

RayzeBio, Inc.

Phase 1 Active not recruiting
21 enrolled
Thoracic

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡